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When it was suggested that we take part in a symposium 
on positron emission tomography (PET) the question asked 
was: Why at Einstein?. Clearly any multimillion dollar in­
vestment at the medical school must be carefully consid­
ered and fully justified, having broad impact extending 
beyond any single department. PET scanning is of po­
tential value in virtually all of the clinical departments and 
many basic sciences. No other tool currently exists with 
the ability to quantitate the basic organic units of carbon, 
oxygen and nitrogen and their compounds in the intact 
living organism. Its relevance to patient care and potential 
use in research have already been demonstrated at many 
centers throughout the country. It has enticing teaching 
possibilities, permitting students to be shown biochemical 
and physiological processes as they occur in humans. 
During the past several years the use of this technique 
has expanded rapidly because of simultaneous devel­
opment in two areas: 
1) rapid synthetic processes have become available for 
a wide variety of organic compounds (radiopharmaceu­
ticals) incorporating short-lived positron emitters which 
are physiologically identical to the metabolic substrates 
within the body, and 
2) computerized axial tomographic techniques have been 
integrated into scintillation detector systems for detecting 
positrons through their annihilation photons. 
A cyclotron PET facility can be visualized by the flow chart 
shown in Figure 1. The unit is composed of many essential 
parts which will be described briefly here. 
Cyclotron Facility 
A cyclotron is one of a class of particle accelerators which 
can be used for radionuclide production by increasing 
the energy of a given type of atomic particle. Several other 
types of accelerators are available, such as the Van de 
Graaf and the linear accelerator (linac); however, the cy-
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clotron is the preferred machine for the production of ra­
dionuclides for biomedical/clinical applications. Particu­
larly attractive is that it can be designed in a relatively 
compact form. The word "cyclotron" derives from the fact 
that the charged particles are accelerated in circular or­
bits of ever increasing radii under the influence of mag­
netic and electric fields in order to propel them to higher 
and higher energies. The particles most commonly em­
ployed in cyclotron accelerators are protons, deuterons, 
alpha particles (4He), and Helium-3 particles. Cyclotrons 
are rated in terms of the maximum energy (Emax). to which 
protons are accelerated; the Emax of other charged par­
ticles are proportional to Z21A, where Z = atomic number, 
and A = atomic mass. Thus a 16 MeV (million electron 
volts) proton unit yields 8 MeV deuterons and 16 MeV 
alpha particles. Individual cyclotrons vary in design fea­
tures, simplicity of operation, reliability, compactness of 
structure, and the target system that is associated with 
the unit for production of the specific radionuclide in ques­
tion. 
Currently, accelerator produced radionuclides are widely 
used in routine nuclear medicine. These routine isotopes 
are not positron emitters and are produced with machines 
which are capable of providing high particle energies and 
beam currents for a wide variety of particles. lodine-123, 
Gallium-67 and lndium-111 are examples of the nuclides 
which are made by medium energy cyclotrons (16 MeV-
40 MeV). 
In order to fully utilize a PET facility it is essential that a 
small medical cyclotron system be located on site since 
most of the major positron emitters which are produced 
have half-lives which are measured only in minutes and 
cannot be transported at great distances. It is imperative 
that they are produced on site and synthesized promptly 
into radiopharmaceuticals for clinical and research ap­
plications. Cyclotron manufacturers have made special 
efforts in recent years to provide units that are relatively 
inexpensive, more compact and perhaps more amenable 
to routine use by fewer technologists than older models. 
The features of some of the cyclotrons designed for med­
ical centers are listed in Table I. 
Cyclotron Targetry and Radiopharmaceutical 
Preparation 
The cyclotron provides the accelerated particles which 
subsequently induce nuclear reactions depending on the 
particle energy and the reaction cross-section. Either gas 
target materials, which are convenient to transport, purify 
and chemically manipulate, or liquid and solid targets 
which usually require dissolution of the target after bom­
bardment, are used conveniently for production of most 
of the positron emitters of clinical interest. Therefore, var­
ious systems are designed to produce radioactive pre-
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Figure 1. PET Facility Lay Out. 
Targetry 
cursors 1n very high yield with high specific activity and 
least operator interaction. These include: 1500, C150, 
c1soo, ,,CO, ,,C02, H,,CN, 13NN, H1BF, 1BFF. 
These radioactive substances are available at the end of 
bombardment or shortly thereafter with remotely operated 
devices in lead shield containers {"hot cells") and are 
produced in very large quantities. For the routine delivery 
of several of these precursors, fully automated production 
under microprocessor control enables handling of curie 
levels of activities with minimal radiation exposure. 
Positron Labeled Radlopharmaceutlcals 
Having produced the desired radioactive element, the 
next step is to formulate a compound incorporating it into 
a usable form. A positron itself is a charged particle emit­
ted by an atom's nucleus. It has a charge equivalent to 
that of the electron or beta minus particle. Positrons have 
Table I. Clinical Cyclotron Models 
Commercial Accelerated Proton energy 
model particles MeV 
LOW ENERGY: 
Cyclotron Corp. p*,d, 4He, 15 
CS15 3He 
Cyclotron Corp. p 16 
CP-16 d (optional) 
Scanditronix 
RNP- 16 p,d 16 
AECUJSW p,d 16 
AECUJSW p,d 10 
MEDIUM ENERGY: 
Cyclotron Corp. 
CS 22 PD p,d 20 
4He, 3He 
(optional) 
Cyclotron Corp. 
CS-30 p,d 26 
Cyclotron Corp. 
CP32 p 8-32 
d (optional) variable 
*p represents proton, d represents deuteron. 
Pharmaceutical 
PreparatiOn 
Patient Positron 
Camera 
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a wide spectrum of energies with an end-point positron 
energy which is characteristic of each positron emitter. 
The positrons travel only a few millimeters through the 
surrounding tissue before encountering electrons and an­
nihilating into two gamma rays, each of 0 . 511 MeV energy 
and emitted characteristically in a direction 180° to each 
other. Positron emitters do not occur in nature. They are 
all produced artificially with the help of the accelerators 
or cyclotrons. 
Positron emitting radiopharmaceuticals which have been 
especially useful in in vivo investigation include Carbon-
11, Nitrogen-13, and Oxygen-15. They have the unique 
advantage of incorporation into naturally occurring mol­
ecules and they do not alter the metabolic fate of these 
compounds in ordinary living systems. The positron em­
itter, Flourine-18 though not in the category of C,N, and 
0 permits labeling in non-interactive sites in the molecule 
in place of hydrogen, often without causing significant 
changes in the response of the biological system to the 
change in the molecular structure. Fluorine is useful in 
that it has a 110 minute half-life, and is one of the few 
positron emitters which may be transported some dis­
tance before use. 
Since most positron emission tomography work is carried 
out with radiopharmaceuticals incorporating C-11 and F-
18, a cyclotron providing particles of energies up to 16 
MeV is necessary to provide sufficient capability for pro­
duction of these radionuclides. The physical properties 
of the positron emitters that are produced with these small 
cyclotrons are given in Table II. 
Short-lived radionuclides can be used safely in larger ac­
tivities because the radiation dose in the patient is pro­
portionate to both the amount of activity administered and 
the rate at which it decays. Administration of higher levels 
of activity makes possible the acquisition of higher count 
rates, statistically more reliable data, and better spatial 
resolution in the final image. 
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Table 11. Physical Properties of Commonly Utilized Positron Emitters 
Radionuclide Half-life (min)! 
carbon-11 20.4 
Nitrogen-13 10.0 
oxygen-15 2.07 
Fluorine-18 110.0 
'The half life is the time required fori of the radioactivity to decay. 
Typical productiont 
reactions 
108 (d,n)11C 
118 (p,n)11C 
14N (p,a)11C 
12C(d,n) 13N 
160(p,a) 13N 
14N(d,n) 150 
20Ne (d,a)16F 
1eo (3He,p)18F 
16Q (4He,p,n)18F 
Precursors and 
simple compounds 
11CO, 11C02, 11CN 
11CH3I, H11C HO 
13N2, 13NH3 
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150-02. H2150, C150, 150-C02 
18F-F2, H1eF, 18F-
tin the production reaction, the first element is the target or material bombarded with the particles. The last element is the resultant products. The 
particles· involved in the reaction are shown. n represents neutron 
Several of the labeled precursors and simple labeled 
compounds like CO, C02, 02, N2, NH3, H20, are readily 
available and they do not need further processing for 
patient use. Incorporation of C-11 or F-18 into various 
biochemical analogs is more elaborate and requires a 
remote synthetic procedure within a very short interval of 
time, usually less than 2 hours. The incorporation of these 
radionuclides into the molecule of interest is accom­
plished via biochemical, enzymatic or other synthetic 
means. Major effort has been directed in recent years to 
the preparation of various saccharides including C-11 glu­
cose and 18F-2 fluoro-2-deoxy-0-glucose ('6F-FDG), neu­
roleptics (11C-dopamine and "C or 18F-dopa), amino acids, 
polyamines, purines, pyrimidines, nucleotides and nu­
cleosides, and fatty acid chains. With the availability of 
these advanced facilities at several centers, more so­
phisticated and novel synthetic procedures are bound to 
be made available and almost any compound conceiv­
ably could be prepared. The routine delivery of such com­
pounds as C-11 palmitate and 18F-FDG is a reality today 
at centers with moderate support facilities. 
Positron Emission Tomographic Scanner 
Radionuclides which decay by positron emission can be 
detected and their distribution imaged by special devices 
which take advantage of the fact that positron emission 
is followed by the emission of two gamma photons in 
exactly opposite directions. Devices which detect this 
coincident radiation are usually referred to as positron 
emission tomographs, PET scanners. Although they have 
been available in various forms for some years, it is only 
with the recent development of small inexpensive com­
puters with sufficient speed and storage capacity that PET 
scanners have become practical for extensive use. 
Positron cameras operate on a principle different from that 
used in the gamma cameras, now commonly encountered 
in nuclear medicine services. The gamma camera nor­
mally uses a parallel-hole collimator to localize the origin 
of the emissions resulting in a low efficiency of detection 
of photons: less than O.D1 per cent of the radiation emitted 
from the patient is actually detected and used for imaging. 
The PET scanner, on the other hand, requires no colli­
mators, thus providing greater sensitivity in terms of useful 
counts per millicurie of radionuclide administered. Res­
olution and sensitivity are both more or less independent 
of the depth of the source in the object, contrary to single 
photon cameras. However, display electronics of a PET 
scanner are much more complex than those of a gamma 
camera; data are stored in a large computer memory and 
cross-sectional images are then reconstructed and dis­
played in a manner similar to an X-ray CT scanner. 
Positron cameras have taken a number of forms over the 
years, but most units which are now commercially avail­
able use a ring of detectors, or several rings, which sur­
round the patient. The principle of detection is as follows. 
The simultaneous detection of two photons in two opposite 
crystals defines a path along which the decay occurred. 
Subsequent decays produce other lines of coincidence. 
This information is stored and then processed by the com­
puter to produce images of the distribution of radioactivity 
in a cross-sectional slice of the subject. If more than one 
ring of detectors is used, several slices can be imaged 
simultaneously. Three rings can produce five slices by 
utilizing coincidences between adjacent rings. Most of the 
newer PET scanners use crystals made of bismuth ger­
manate (BGO) which has a density almost equal to that 
of lead, and thus offers a higher stopping power for the 
511 KeV gamma photons as compared with the sodium 
iodide (Nal) detectors used in conventional gamma cam­
eras. PET systems are capable of high count rates for 
dynamic studies, multiple slices, good resolution, rapid 
image reconstruction and absolute regional quantitation 
of radioactivity. 
Clinical Applications of PET Scanning Procedures 
The most dramatic impact of PET scanning so far has 
been in neurophysiology research. In clinical practice the 
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potential exists for sophisticated diagnosis of psychiatric 
disorders, stroke and epilepsy. The technique may also 
prove useful in Huntington's chorea, tardive dyskinesia, 
growth rates in brain tumors, and senile dementia, to name 
a few. 
Areas of abnormal activity have been shown in schizo­
phrenics with restoration to normal patterns after drug 
therapy. The portion of the visual cortex used for observ­
ing an object can be clearly shown on the PET scan (Fig­
ure 2). In epileptics the utilization of glucose during an 
induced seizure can be used to identify the focus of the 
disorder. Neurosurgeons at the University of California are 
presently using PET to distinguish between areas of pri­
mary epileptic foci of the severe type and healthy brain 
Figure 2. Study with 1Bf-deoxyglucose showing response of the pri­
mary (PVC) and associative (AVC) visual cortex from eyes-closed 
control to white light stimulation to complex visual scene of a park. 
The control and the white light stimulation are the same subject, while 
the complex stimulation was a different subject, the tomographic levels 
of whom do not exactly correspond to the first subject's and the line 
drawings. Note the increasing metabolic activity of the visual cortex 
from the eyes-closed state to the increasing complexity of visual stim-
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as an aid to direction in surgery. Infarcts can be quanti­
tated in scans of the heart and clear visualization of the 
pancreas can be obtained using metabolic substrates. 
Regional permeability characteristics and blood flow in 
various tissues including brain and lung using 150 labeled 
water and 11C labeled alcohols is another area of inves­
tigation attempted with this facility. The labeled amino 
acids might prove useful in imaging pancreas and other 
tissues of rapid amino acid turnover. The fact that malig­
nant tumors consume glucose at a higher rate than the 
surrounding tissue may be utilized for measuring the ef­
ficacy of chemotherapy through the drug's ability to alter 
labeled glucose metabolism using PET scan procedures. 
Thus blood volume, oxygen and glucose metabolism, amino 
ulation. Also note in the eyes-closed study the delineation of the pos­
terior-parietal cortex from Brodman area 19 of the associative visual 
cortex. (Legend: D, caudate nucleus; E, thalamic nuclei; F, atrium of 
lateral ventricle; G, putamen and globus pallidus; H, anterior horn of 
lateral ventricle; I, internal capsule; J, ex1ernal capsule. Adapted from 
Phelps, M. E. by permission from Seminars in Nuclear Medicine 11: 
32-49.) 
Positron Emission Tomogr
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acid transport, protein synthesis, blood flow, receptor 
measurements, labeled antibodies for tumor localization, 
efficacy of chemotherapy drugs, trace metal metabolism, 
body nitrogen and electrolyte measurement are among 
the many diverse clinical applications envisaged using 
the unique spatial resolution in dynamic mode attainable 
with the use of the PET facility. 
Layout and Cost of the PET Facility 
The PET facility requires a large group of skilled spe­
cialists for optimal utilization. An estimate of initial costs 
is in the range of three million dollars, depending upon 
the choice of cyclotron, the remote processing equipment 
and hot laboratory, PET camera and the building facility. 
Allocation of resources has become a major problem for 
hospital and medical school administration. We can no 
longer have everything. However, we cannot afford to 
make priorities solely on the basis of immediate needs. 
The responsibility of the medical school is to education. 
This process includes not only a presentation of the past 
and current state of the art, but also projection into the 
future. Medical graduates must be prepared to under­
stand and utilize future development. The faculty must be 
forward-looking in order to carry out this task. A faculty 
functioning at the forefront of modern medicine clearly 
can help create a new physician who will offer future pa­
tients the greatest benefit. Medical faculties have broad 
and proved excellence in teaching and research. The 
acquisition of a PET facility will help them to achieve this 
potentiaL and to maintain the position of the medical school 
as a leader in medical education and research, a position 
which is essential in continuing to attract first-rate students 
and faculty. 
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Commentary by Dr. Leslie Wolfson 
In human disease states, major insights have already been 
obtained through PET. With the labeled glucose analogs 
a depressed metabolic rate has been reported interictally 
in abnormal brain tissue, which is acting as an epileptic 
focus. Diminished cortical metabolism (especially in the 
frontal lobes) has been noted in patients with Alzheimer's 
disease, a disease which involves cortex, while dimin­
ished subcortical metabolism has been noted in patients 
with Huntington's disease, which involves subcortical 
structures. The pattern of metabolism in patients with stroke 
also is being actively investigated as well as in many other 
neurologic diseases. 
The localized nature of these diseases in conjunction with 
the functional specialization of brain, makes the three di­
mensional resolving power of PET a powerful tool in un­
derstanding pathophysiology. This ability to localize brain 
regions with abnormal function and perhaps subtle struc­
tural abnormalities is the contribution of PET. The pres­
ence of a large number of productive research groups in 
the Departments of Neuroscience, Neuropathology, Neu­
rosurgery and Neurology allow us to approach PET from 
a position of scientific strength. The likelihood that major 
understanding of diseases of the central nervous system 
will result from the unique capabilities of PET scanning 
dictate that we develop this area so that we may be in a 
position to lead in these discoveries. 
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Commentary by Dr. Wagner H. Bridger 
Structural and metabolic brain abnormalities have been 
hypothesized to be involved in many psychiatric disor­
ders. This has been inferred from the aberrant findings in 
respect to neurotransmitters, endocrinological measure­
ments, and the EEG. These are all peripheral measure­
ments and post-mortem studies have not revealed major 
structural pathology. The assumption that functional brain 
disturbances are involved can only be confirmed through 
a technology such as PET. Future breakthroughs in psy­
chiatric diagnosis and treatment will come about primarily 
throuah such a new technoloav. 
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Commentary by Dr. James Scheuer 
Positron emission tomographic units for cardiovascular 
studies are now in place in several large institutions in 
this country. The capability of this approach in clinical 
research and in diagnosis has only just begun to be tapped. 
Because of the high resolution for localizing changes in 
isotope content and distribution, non-invasive studies can 
be performed in intact humans which provide precise 
information about small areas of myocardium in the beat­
ing heart. For instance, rates of coronary flow can be 
measured in a 1 cm3 volume of myocardium and changes 
monitored. Using radioactively tagged substrates of var­
ious types, cellular metabolism of the heart can be mea­
sured in the same small segments using amino acids, 
fatty acids and carbohydrates. Using other tagged sub­
stances, the myocardium can be labeled and the ge­
ometry of the ventricular wall and the mechanical perfor­
mance of small segments of myocardium can be followed. 
Thus, for instance, a segment of myocardium that may 
be subjected to ischemia in a patient with coronary artery 
disease could have blood flow through that area, metab­
olism, and mechanical performances all measured during 
the ischemic event and as the heart responds to the treat­
ment of the ischemic event. This technique can be applied 
to patients with myocardial infarction, myocardial hyper­
trophy, myocardiopathies, some forms of congenital heart 
disease and even a current clinical enigma, acute myo­
carditis. It is difficult to forecast the ultimate role of this 
tool in clinical cardiology, but clearly it will make major 
contributions to diagnosis of disease and to monitoring 
treatment of patients with various forms of heart disease. 
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The Editor's Commentary 
With inflation and public service cutbacks, our first re­
action to enthusiastically presented but expensive new 
medical technologies is to smile and check the wherea­
bouts of our wallets. But even in these times, if there is a 
vision that promises revolutionary, or even utopian changes 
in the way we view patients and their diseases we must 
not fear a commitment now at tomorrow's expense. Rather 
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we must rely on both the present facts and on our intuitions 
about the future in order to evaluate a costly investment 
such as one as Positron Emission T0mography. In their 
article, Dr. Blaufox and colleagues have presented the 
essence of the technique and its promise. We shall review 
selected aspects of the topic in order to strain from a 
growing body of scientific experience a sense of why PET 
has generated both enthusiasm and frustration in those 
who have come to know it intimately. 
The great promise of PET is the quantitation of in vivo 
biochemical processes. But it should be kept in mind that 
the ability to supply a number is not a guarantee of usable 
or useful information. The Computerized Axial Toma­
graphic (CAT) scanner supplies quantitated densities, but 
it is now forgotten that once it was hoped to correlate 
radiographic density with tumor histology. A critical eval­
uation of PET therefore must center around the prospects 
for an accurate and reproducible analysis of data which 
has scientific and clinical utility. To this end, three ques­
tions are posed: first, can consistent measurements be 
made; second, what precisely is being measured; finally, 
what is the significance of that which is measured. 
A serious drawback to the applicability of PET scanning 
in the clinical situation lies in the strict constraints placed 
on the timing of studies due to the rapid decay of positron 
emitters. While semi-automated cyclotrons and radio­
pharmaceutical synthesizing equipment greatly increase 
the speed (and safety) of the preliminary steps of a PET 
study, it is not so easy to coordinate all the clinical and 
technological personnel necessary and to prepare the 
patient for the study. Nuclear bombardment, chemical 
synthesis, radiopharmaceutical and patient transport, in­
travenous injection, multiple simultaneous venous sam­
pling for measuring blood levels, and scanning must all 
work smoothly and routinely. These are not insurmount­
able problems to the determined investigator, but an un­
predictable, though probable, event such as last minute 
scheduling mix-ups, or lack of patient cooperation, (cur­
rent scans require 5-6 minutes of absolute stillness) or 
equipment malfunction can frustrate an entire chain of 
command. It is for this reason that Fluorine-18 labeled 
radiopharmaceuticals with half-lives of 110 minutes, al­
lowing a certain amount of flexibility, are replacing the 
Carbon-11 tags (T·� = 20 minutes) for clinical studies. 
A more profound difficulty is in the synthesis of the key 
element in the PET technology, the radiopharmaceutical. 
For any new radiochemical-and the great selling point 
of PET is its potential applicability to a study of virtually 
any compound of interest-a whole new methodology of 
chemical synthesis must be developed. For the synthesis 
of a positron-emitting target to be practical three criteria 
must be satisfied: it must be fast, efficient in yield quan­
tities, and high in specific activity. 
positron Emission Tomography 
The maximum period of time for synthesis again depends 
upon the emitter. Both biosynthetic routes (e.g. ,  14C-glu­
cose from plants and algae) and radio-labeling of pre­
existing reagents have been used with success. Yield is 
the amount of specific radiopharmaceutical produced rel­
ative to the amount of labeled target. The need for uni­
formity of radiopharmaceutical varies with the type of study. 
For example, in a localizing scan for tumor-associated 
glucose metabolism, the precise carbon atom on the glu­
cose molecule to be labeled is not critical. On the other 
hand, in a quantitative study of dopamine receptors, the 
specific location of the F-18 on the labeled haloperidol 
determines its binding properties. A random mixture of 
forms ot F-18 haloperidol, each with its own interaction 
with dopamine receptors, spells experimental confusion, 
if not disaster. Finally, the importance of specific activity­
the ratio of positron-emitting compound to unlabeled com­
pound, or "carrier" - also is determined by the experi­
mental design. If the compound being studied is ubiqu­
itous in the body, such as glucose, a high specific activity 
during synthesis is not useful. In this case, the dilution of 
the radiopharmaceutical must be determined by meas­
uring the blood levels of labeled glucose. However, in a 
receptor study a high specific activity of ligand is the sine 
qua non. The amount of specific binding of radiolabeled 
ligand to receptor is so small that extremely minute quan­
tities of the labeled agent must be administered to avoid 
a saturation of the specific binding and an overflow onto 
the non-specific binding sites. Therefore, every ligand 
molecule should ideally be labeled in order to avoid a 
high binding background and uninterpretable results. 
The second question is: What precisely is being mea­
sured? Because biological compounds are being used, 
they will undergo compartmentalization and metabolism 
consistent with normal physiological processes. But if the 
radiolabeled agent is not strictly identical to its endoge­
nous counterpart, or if the subject has disease which 
changes the pertinent physiology, complexities will arise. 
Studies with labeled glucose are extremely limited be­
cause metabolism through glycolysis is well underway 
within five minutes. Indeed, phosphorylation must occur 
in order to assure a proper study, for it is the phospho­
rylated metabolites of glucose which are impermeant to 
the cell membrane and thus become the measured "pool" 
of label inside the cell. Unfortunately, in the case of glu­
cose, metabolism subsequently produces labeled sub­
stances, e. g. , C02, which then diffuse out of the cell. 
Therefore, studies must be done quickly with full knowl­
edge of the kinetics involved. Analogues of substances 
such as 2 deoxy-D-glucose, which remain trapped in the 
cells, avoid the time constraint but introduce other factors 
which were only fully described after years of basic re­
search by Sokoloff, Revich, and colleagues (Sokoloff et 
al. , 1977). How the range of human pathophysiologies will 
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affect the basic assumptions about the biological activity 
of each radiopharmaceutical is unclear. 
Similarly, studies of dopamine metabolism in the brain with 
the fluorinated precursor 5-[18F] fluorodopa are hampered 
by the fluorine substitution itself, which makes the adja­
cent hydroxyl more acidic-and ten times more suscep­
tible to methylation than unfluorinated dopa. The meth­
ylated precursor acts quite differently in the brain from 
dopa, making conclusions from such studies tentative at 
best. The upshot is that behind any human study in vivo 
must be a firm understanding of the basic biochemistry 
involved from in vitro and animal studies. 
Finally the most difficult question, and perhaps the most 
controversial is: What is the ultimate usefulness of the 
information provided by PET? Clearly, considering only 
the nature of the data itself there are theoretical limitations. 
Positrons travel up to 6 mm before annihilation; of the 
biologically useful emitters Fluorine-18 produces posi­
trons which travel the shortest distance and thus provides 
the greatest resolving power. Scanners presently are ca­
pable of assessing minimal volume units of around 1-2 
ml; however, volume units of 0. 05--0.1 ml will be distin­
guishable in the near future. This is not the resolving power 
of an in vitro autoradiograph - only the larger elements 
of the nervous system could be investigated. Most tracts 
and individual nuclei will be inaccessible to conventional 
PET, which unfortunately, is the level at which a true rev­
olution in neurological understanding must occur. 
Data from PET about disease states must always be viewed 
with respect for the subtleties of each clinical situation. 
Interpreting one variable, regional glucose metabolism in 
a series of patients with stroke, for example, each with a 
different serum glucose level, different baseline metabolic 
requirements, past medical histories, and present clinical 
courses, will be a difficult task for any clinician - investi­
gator. Given the difficulties with which new synthetic routes 
for new radiopharmaceuticals are developed one can easily 
picture a scenario in which a few tantalizing discoveries 
are made quickly with the present agents, followed by 
years of slow laborious work in order to make sense out 
of the myriad clinical situations. 
Given the technology's prospects for slow progress, we 
must address the most fundamental question: what pro­
found new understanding of the brain can we expect to 
learn from PET? Its major achievement so far, that is, 
seeing pictures of living brain "light up" with metabolic 
activity, will not burn in the imagination of neuroscientists, 
neurologists, and psychiatrists (a jaded lot) for long. Even 
today's most exciting findings besides the precise func­
tional mapping of cortex, that is, the changes in brain 
metabolism seen in patients with schizophrenia, Hunting­
ton's, and Alzheimer's Disease, can, on critical analysis, 
be viewed as epiphenomenal. The local changes in glu-
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cose metabolism may be only secondary or tertiary 
changes, far removed from the causative molecular events 
in these diseases. Perhaps it is too early to say, but it 
seems unlikely that a parameter such as brain metabolism 
will point to the fundamental substrates of neurological 
and psychiatric disorders, which lie in the genome, in the 
specificity of neuronal cell-types, their interactions, with 
each other and their environment within and beyond the 
brain. 
This scenario, however, is only an extrapolation based 
upon the progress in PET so far. The path described is 
not the only one to follow. For example, an alternative to 
the slow development of each radiopharmaceutical in­
dependently would be a single technology easily adapt­
able to many agents. Production of positron-emitting mon­
oclonal antibodies by a standard technology of incubating 
a monoclonal antibody-producing hybridoma culture or 
cell-free protein synthesizing system with radiolabeled 
amino acids would answer such a need. Thus in vivo 
localization with positron-emitting antibodies to neuro­
transmitters, receptors, neural-surface and tumor anti­
gens all could be achieved with essentially the same syn­
thetic route. During the synthesis, time might be a limiting 
factor, but yield would be good, purification relatively easy, 
and specific activity excellent with multiple positron-emit­
ting residues per antibody molecule. 
The great difficulty of course with using a macromolecule 
such as an antibody for a radiolabeled probe in the brain 
is the problem of penetration across the blood-brain bar­
rier. While a certain minimal amount of antibody does 
cross the blood-brain barrier by diffusion to bind specif­
ically with its antigen, techniques to temporarily open up 
the blood-brain barrier to larger molecules are presently 
being investigated. Injections of hyperosmotic solutions 
such as 2M urea or 5 per cent NaCI have been shown to 
reversibly open the blood-brain barrier in animal models 
(Rapoport et al., 1972). High pC02 and other compounds 
such as dilute mercuric chloride have similar effects (Mayer 
et al., 1959). 
A high specific activity of positron-emitting antibody would 
open up the possibility for a higher resolutional tomo­
graphic scan. While a positron does travel a radius of a 
few millimeters from the nucleus of its emission to the point 
of its annihilation with an electron, this should not establish 
an absolute minimal limit on scanning resolution. If the 
decay characteristics of the emitter are precisely known, 
one can construct a sphere of probability of annihilation 
emanating from the central point of emission. Given small 
enough volume units, a Fourier transform of the photon 
68 
emission data points should describe the theoretical cen­
tral points of positron emission. While radiation levels and 
the scatter produced by photon trajectories not precisely 
at 180° to each other may ultimately be limiting, this sec­
ondary analysis of data points might bring the resolution 
of the PET scan down to the level of neurological tracts 
and nuclei, which would begin to satisfy the needs of 
neurologists and neuroscientists. 
Combining these methodologies, a Monoclonal Open-en­
dothelial Ultraresolutional Scintillation Emitter scan would 
be called a MOUSE scan to continue and perhaps com­
plete the trend in nuclear medicine and radiology to name 
technologies after household animals and plants. After 
initial embarrassment, the MOUSE scan would prove to 
be a revolutionary and flexible tool for the diagnosis and 
study of neurological and oncological disease. Such a 
technology would be the long-needed bridge between 
basic research on the expression and change of biolog­
ical molecules and the clinical state. Thus in conclusion 
of this symposium, let us say that any decision on the 
future of the PET scan framed by the constraints of the 
moment must yet be with an eye towards syntheses of 
technologies seen still only in the imagination. 
Todd Charlton Sacktor 
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